Abstract

Stroke is an acute and focal neurological syndrome characterized by clinical deficits resulting from vascular injuries such as infarction or hemorrhage in the central nervous system. Given the prevalence of multiple comorbidities among stroke patients, they often find themselves on more than five medications, falling into the category of polypharmacy. Beyond treatments aimed at improving stroke outcomes and managing comorbid conditions, the presence of additional diseases may necessitate new therapies, potentially leading to side effects that can intersect and exacerbate the existing disease. This case report aims to present instances of hyperglycemia in stroke patients undergoing high-dose glucocorticoid therapy and discuss potential strategies to address this issue. In this particular case, human insulin was selected to rapidly control the patient's hyperglycemic condition. Subsequently, adjustments to basal and bolus insulin doses were made based on the frequency of use and duration of action of the glucocorticoid, specifically methylprednisolone. In conclusion, the hyperglycemia induced by glucocorticoids was identified through postprandial sugar monitoring, necessitating treatment through modifications to basal and bolus insulin doses. Strategies for managing hyperglycemia should be tailored to the pharmacokinetics of glucocorticoids and insulin.

There is no Figure or data content available for this article

References

• Murphy SJ, Werring DJ. Stroke: causes and clinical features. Medicine (Abingdon). Sep 2020;48(9):561-566. doi:10.1016/j.mpmed.2020.06.002
• Imanda A, Martini S, Artanti KD. Post hypertension and stroke: A case control study. Kesmas: National Public Health Journal. 2019;13(4)doi:10.21109/kesmas.v13i4.2261
• Alrabghi L, Alnemari R, Aloteebi R, et al. Stroke types and management. Int J Community Med Public Health. 2018;5:3715. doi:10.18203/2394-6040.ijcmph20183439
• Venketasubramanian N, Yoon BW, Pandian J, Navarro JC. Stroke Epidemiology in South, East, and Southeast Asia: A Review. J Stroke. Sep 2017;19(3):286-294. doi:10.5853/jos.2017.00234
• Park JH, Ovbiagele B. Optimal combination treatment and vascular outcomes in recent ischemic stroke patients by premorbid risk level. J Neurol Sci. Aug 15 2015;355(1-2):90-3. doi:10.1016/j.jns.2015.05.028
• Tramacere I, Boncoraglio GB, Banzi R, et al. Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Medicine. 2019/03/26 2019;17(1):67. doi:10.1186/s12916-019-1298-5
• Hosoi T, Yamana H, Tamiya H, et al. Association between comprehensive geriatric assessment and polypharmacy at discharge in patients with ischaemic stroke: A nationwide, retrospective, cohort study. EClinicalMedicine. Aug 2022;50:101528. doi:10.1016/j.eclinm.2022.101528
• Lum MV, Cheung MYS, Harris DR, Sakakibara BM. A scoping review of polypharmacy interventions in patients with stroke, heart disease and diabetes. Int J Clin Pharm. Apr 2020;42(2):378-392. doi:10.1007/s11096-020-01028-x
• Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol. May 2014;70(5):575-81. doi:10.1007/s00228-013-1639-9
• Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. Mar 15 2011;335(1):2-13. doi:10.1016/j.mce.2010.04.005
• Trence DL. Management of patients on chronic glucocorticoid therapy: an endocrine perspective. Prim Care. Sep 2003;30(3):593-605. doi:10.1016/s0095-4543(03)00038-1
• Wardani IS. Steroid Induced Diabetes Mellitus. Jurnal Kedokteran Unram 2023;12(1):1372 – 1376. doi:10.29303/jku.v12i1.852
• Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. Dec 2006;29(12):2728-9. doi:10.2337/dc06-1499
• Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65(4):324-32. doi:10.1159/000365892
• Kwon S, Hermayer KL, Hermayer K. Glucocorticoid-induced hyperglycemia. Am J Med Sci. Apr 2013;345(4):274-277. doi:10.1097/MAJ.0b013e31828a6a01
• Tufton N, Ahmad S, Rolfe C, Rajkariar R, Byrne C, Chowdhury TA. New-onset diabetes after renal transplantation. Diabet Med. Nov 2014;31(11):1284-92. doi:10.1111/dme.12534
• Kolmos M, Christoffersen L, Kruuse C. Recurrent Ischemic Stroke - A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. Aug 2021;30(8):105935. doi:10.1016/j.jstrokecerebrovasdis.2021.105935
• Suh S, Park MK. Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem. Endocrinol Metab (Seoul). Jun 2017;32(2):180-189. doi:10.3803/EnM.2017.32.2.180
• Wallace MD, Metzger NL. Optimizing the Treatment of Steroid-Induced Hyperglycemia. Ann Pharmacother. Jan 2018;52(1):86-90. doi:10.1177/1060028017728297
• Shah P, Kalra S, Yadav Y, et al. Management of glucocorticoid-induced hyperglycemia. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2022:1577-1588. doi:10.2147/DMSO.S330253
• van Raalte DH, Nofrate V, Bunck MC, et al. Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol. Apr 2010;162(4):729-35. doi:10.1530/eje-09-1034
• Bonaventura A, Montecucco F. Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract. May 2018;139:203-220. doi:10.1016/j.diabres.2018.03.006
• Yasuda K, Hines E, 3rd, Kitabchi AE. Hypercortisolism and insulin resistance: comparative effects of prednisone, hydrocortisone, and dexamethasone on insulin binding of human erythrocytes. J Clin Endocrinol Metab. Nov 1982;55(5):910-5. doi:10.1210/jcem-55-5-910
• van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. Feb 2009;39(2):81-93. doi:10.1111/j.1365-2362.2008.02067.x
• van Genugten RE, van Raalte DH, Muskiet MH, et al. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial. Eur J Endocrinol. Mar 2014;170(3):429-39. doi:10.1530/eje-13-0610
• van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care. Feb 2011;34(2):412-7. doi:10.2337/dc10-1677
• Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. Jan 2012;97(1):16-38. doi:10.1210/jc.2011-2098
• Kemenkes R. Pedoman Nasional Pelayanan Kedokteran Tatalaksana Diabetes Melitus Tipe 2 Dewasa. Jakarta: Kementerian Kesehatan RI. 2020;
• Oyer DS, Shah A, Bettenhausen S. How to manage steroid diabetes in the patient with cancer. J Support Oncol. Oct 2006;4(9):479-83.
• Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. Jun 2011;96(6):1789-96. doi:10.1210/jc.2010-2729

There is no Supplemental content for this article.

How to Cite This

Article Metrics

Copyright and Permissions

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

• BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability